Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Endocrinological Investigation|December 28, 2020
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapyL Brilli, R Danielli, M Campanile, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 8, 2022
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic FeaturesAnna M Di Giacomo, Andrea Guarnieri, Sergio A Tripodi, et al.
British Journal of Cancer|May 27, 2015
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patientsP F Ferrucci, S Gandini, A Battaglia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF<sup>v600</sup> mutation-positive melanoma receiving adjuvant vemurafenibP A Ascierto, K D Lewis, A M Di Giacomo, et al.
ESMO Open|March 12, 2021
Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup studyM Guida, S Strippoli, M Maule, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyA M Di Giacomo, P A Ascierto, P Queirolo, et al.
Cancers|February 3, 2021
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) StudyMichele Guida, Nicola Bartolomeo, Pietro Quaglino, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2023
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profilePaolo A Ascierto, Anna M Di Giacomo, Vanna Chiarion Sileni, et al.
Expert Opinion on Biological Therapy|February 4, 2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabFrancesco Pantano, Marco Russano, Alfredo Berruti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
Pageof 4